`Filed: June 9, 2015
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`________________
`
`AMNEAL PHARMACEUTICALS LLC and PAR PHARMACEUTICAL, INC.
`
`Petitioners,
`
`v.
`
`JAZZ PHARMACEUTICALS, INC.
`
`Patent Owner
`________________
`
`Case IPR2015-00547
`
`Patent 7,765,107
`________________
`
`MOTION TO SEAL AND FOR ENTRY OF PROTECTIVE ORDER
`
`
`
`
`
`
`
`
`
`
`
`
`Motion to Seal and for Entry of Protective Order
`
`
`
`
`
`
`
`
`
`
`
`
`
`IPR2015-00547
` Patent 7,766,107
`
`Pursuant to 37 C.F.R. § 42.14, Patent Owner Jazz Pharmaceuticals, Inc,
`
`respectfully requests that the Patent Trial and Appeal Board (the “Board”) seal the
`
`unredacted version of Exhibit 2033, Exhibit 2037 in its entirety, and the unredacted
`
`version of Patent Owner Reply to Petitioners’ Failure to Name All Real Parties In
`
`Interest (“Patent Owner Reply”), which discusses Exhibit 2037. Pursuant to
`
`Appendix B to the Trial Practice Guide, Patent Owner is concurrently filing non-
`
`confidential versions of Exhibit 2033 and the Patent Owner Reply, with the
`
`confidential material reacted.
`
`Page 7, lines 15-16 of Exhibit 2033 contain Par Inc.’s declarant, Barry
`
`Gilman’s, home address. That address is being redacted pursuant to Mr. Gilman’s
`
`request during his June 4, 2015 deposition. Exhibit 2037, and the portion of the
`
`Patent Owner Reply discussing that exhibit, contain the parties’ business
`
`confidential information.1 Good cause therefore exists for sealing these
`
`documents. Attached hereto is the Board’s Default Protective Order contained in
`
`Appendix B to the Trial Practice Guide.
`
`
`
`1 Jazz does not object to Amneal Pharmaceuticals LLC accessing Ex. 2037 and
`
`the unredacted Patent Owner Reply. Since these documents contain Par’s business
`
`confidential information, however, Jazz is filing them with access to “Filing Party
`
`and Board Only.”
`
`
`
`
`
`Motion to Seal and for Entry of Protective Order
`
`
`
`
`
`
`
`
`
`
`
`
`
`IPR2015-00547
` Patent 7,766,107
`
`For the foregoing reasons, Patent Owner respectfully requests that the Board
`
`enter an Order sealing the unredacted version of Exhibit 2033, Exhibit 2037 in its
`
`entirety, and the unredacted version of the Patent Owner Reply, which discusses
`
`Exhibit 2037, and requiring the parties to abide by the attached Protective Order.
`
`Date: June 9, 2015
`
` Respectfully submitted,
`
`By: /F. Dominic Cerrito (Reg. No. 38,100)/
` F. Dominic Cerrito (Reg. No. 38,100)
` Evangeline Shih (Reg. No. 50,170)
` Frank C. Calvosa (Reg. No. 69,064)
`QUINN EMANUEL URQUHART &
`SULLIVAN, LLP
`51 Madison Avenue, 22nd Floor
`New York, NY 10010
`General Tel: (212) 849-7000
`Fax: (212) 849-7100
`nickcerrito@quinnemanuel.com
`evangelineshih@quinnemanuel.com
`frankcalvosa@quinnemanuel.com
`
`John V. Biernacki
`Reg. No. 40,511
`JONES DAY
`North Point
`901 Lakeside Avenue
`Cleveland, Ohio 44114
`General Tel: (216) 586-3939
`Fax: (216) 579-0212
`jvbiernacki@jonesday.com
`Attorneys for Jazz Pharmaceuticals, Inc
`
`
`
`
`
`
`
`
`
`
`
`
`2
`
`
`
`
`
`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`________________
`
`AMNEAL PHARMACEUTICALS LLC and PAR PHARMACEUTICAL, INC.
`
`Petitioners,
`
`v.
`
`JAZZ PHARMACEUTICALS, INC.
`
`Patent Owner
`________________
`
`Case IPR2015-00547
`
`Patent 7,765,107
`________________
`
`
`
`PROTECTIVE ORDER
`
`
`
`
`
`
`
`This standing protective order governs the treatment and filing of
`
`confidential information, including documents and testimony.
`
`1. Confidential information shall be clearly marked “PROTECTIVE
`
`ORDER MATERIAL.”
`
`2. Access to confidential information is limited to the following individuals
`
`who have executed the acknowledgment appended to this order:
`
`(A) Parties. Persons who are owners of a patent involved in the proceeding
`
`and other persons who are named parties to the proceeding.
`
`(B) Party Representatives. Representatives of record for a party in the
`
`proceeding.
`
`(C) Experts. Retained experts of a party in the proceeding who further
`
`certify in the Acknowledgement that they are not a competitor to any party, or a
`
`consultant for, or employed by, such a competitor with respect to the subject matter
`
`of the proceeding.
`
`(D) In-house counsel. In-house counsel of a party.
`
`(E) Other Employees of a Party. Employees, consultants or other persons
`
`performing work for a party, other than in-house counsel and in-house counsel’s
`
`support staff, who sign the Acknowledgement shall be extended access to
`
`confidential information only upon agreement of the parties or by order of the
`
`Board upon a motion brought by the party seeking to disclose confidential
`
`
`
`
`
`
`
`
`
`
`information to that person. The party opposing disclosure to that person shall have
`
`the burden of proving that such person should be restricted from access to
`
`confidential information.
`
`(F) The Office. Employees and representatives of the Office who have a
`
`need for access to the confidential information shall have such access without the
`
`requirement to sign an Acknowledgement. Such employees and representatives
`
`shall include the Director, members of the Board and their clerical staff, other
`
`support personnel, court reporters, and other persons acting on behalf of the Office.
`
`(G) Support Personnel. Administrative assistants, clerical staff, court
`
`reporters and other support personnel of the foregoing persons who are reasonably
`
`necessary to assist those persons in the proceeding shall not be required to sign an
`
`Acknowledgement, but shall be informed of the terms and requirements of the
`
`Protective Order by the person they are supporting who receives confidential
`
`information.
`
`3. Persons receiving confidential information shall use reasonable efforts to
`
`maintain the confidentiality of the information, including:
`
`(A) Maintaining such information in a secure location to which persons not
`
`authorized to receive the information shall not have access;
`
`
`
`
`
`
`
`
`
`
`
`
`(B) Otherwise using reasonable efforts to maintain the confidentiality of the
`
`information, which efforts shall be no less rigorous than those the recipient uses to
`
`maintain the confidentiality of information not received from the disclosing party;
`
`(C) Ensuring that support personnel of the recipient who have access to the
`
`confidential information understand and abide by the obligation to maintain the
`
`confidentiality of information received that is designated as confidential; and
`
`(D) Limiting the copying of confidential information to a reasonable number
`
`of copies needed for conduct of the proceeding and maintaining a record of the
`
`locations of such copies.
`
`4. Persons receiving confidential information shall use the following
`
`procedures to maintain the confidentiality of the information:
`
`(A) Documents and Information Filed With the Board.
`
`(i) A party may file documents or information with the Board under seal,
`
`together with a non-confidential description of the nature of the confidential
`
`information that is under seal and the reasons why the information is confidential
`
`and should not be made available to the public. The submission shall be treated as
`
`confidential and remain under seal, unless, upon motion of a party and after a
`
`hearing on the issue, or sua sponte, the Board determines that the documents or
`
`information do not to qualify for confidential treatment.
`
`
`
`
`
`
`
`
`
`
`
`
`(ii) Where confidentiality is alleged as to some but not all of the information
`
`submitted to the Board, the submitting party shall file confidential and non-
`
`confidential versions of its submission, together with a Motion to Seal the
`
`confidential version setting forth the reasons why the information redacted from
`
`the non-confidential version is confidential and should not be made available to the
`
`public. The nonconfidential version of the submission shall clearly indicate the
`
`locations of information that has been redacted. The confidential version of the
`
`submission shall be filed under seal. The redacted information shall remain under
`
`seal unless, upon motion of a party and after a hearing on the issue, or sua sponte,
`
`the Board determines that some or all of the redacted information does not qualify
`
`for confidential treatment.
`
`(B) Documents and Information Exchanged Among the Parties. Information
`
`designated as confidential that is disclosed to another party during discovery or
`
`other proceedings before the Board shall be clearly marked as “PROTECTIVE
`
`ORDER MATERIAL” and shall be produced in a manner that maintains its
`
`confidentiality.
`
`(j) Standard Acknowledgement of Protective Order. The following form
`
`may be used to acknowledge a protective order and gain access to information
`
`covered by the protective order:
`
`
`
`
`
`
`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`________________
`
`AMNEAL PHARMACEUTICALS LLC and PAR PHARMACEUTICAL, INC.
`
`Petitioners,
`
`v.
`
`JAZZ PHARMACEUTICALS, INC.
`
`Patent Owner
`________________
`
`Case IPR2015-00547
`
`Patent 7,765,107
`________________
`
`Acknowledgment for Access to Protective Order Material
`
`I ____________________________, affirm that I have read the Protective
`
`Order; that I will abide by its terms; that I will use the confidential information
`
`only in connection with this proceeding and for no other purpose; that I will only
`
`allow access to support staff who are reasonably necessary to assist me in this
`
`proceeding; that prior to any disclosure to such support staff I informed or will
`
`inform them of the requirements of the Protective Order; that I am personally
`
`responsible for the requirements of the terms of the Protective Order and I agree to
`
`submit to the jurisdiction of the Office and the United States District Court for the
`
`
`
`
`
`
`
`
`
`
`Eastern District of Virginia for purposes of enforcing the terms of the Protective
`
`Order and providing remedies for its breach.
`
`
`
`DATE:_____________
`
`
`
`SIGNED:______________________________________________
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`________________
`
`AMNEAL PHARMACEUTICALS LLC and PAR PHARMACEUTICAL, INC.
`
`Petitioners,
`
`v.
`
`JAZZ PHARMACEUTICALS, INC.
`
`Patent Owner
`________________
`
`Case IPR2015-00547
`
`Patent 7,765,107
`________________
`
`
`CERTIFICATE OF SERVICE
`
`
`
`
`
`Motion to Seal and for Entry of Protective Order
`
`
`
`
`
`
`
`
`
`
`
`
`
`IPR2015-00547
` Patent 7,766,107
`
`CERTIFICATE OF SERVICE
`
`Pursuant to 37 C.F.R. § 42.6(e), the undersigned hereby certify that Patent
`
`Owner’s MOTION TO SEAL AND FOR ENTRY OF PROTECTIVE ORDER
`
`was served on June 9, 2015 by filing this document through the Patent Review
`
`Processing System, as well as e-mailing a copy to dvarughe-PTAB@skgf.com and
`
`dsterlin-PTAB@skgf.com.
`
`Date: June 9, 2015
`
` Respectfully submitted,
`
`By: /F. Dominic Cerrito (Reg. No. 38,100)/
` F. Dominic Cerrito (Reg. No. 38,100)
` Evangeline Shih (Reg. No. 50,170)
` Frank C. Calvosa (Reg. No. 69,064)
`QUINN EMANUEL URQUHART &
`SULLIVAN, LLP
`51 Madison Avenue, 22nd Floor
`New York, NY 10010
`General Tel: (212) 849-7000
`Fax: (212) 849-7100
`nickcerrito@quinnemanuel.com
`evangelineshih@quinnemanuel.com
`frankcalvosa@quinnemanuel.com
`
`John V. Biernacki
`Reg. No. 40,511
`JONES DAY
`North Point
`901 Lakeside Avenue
`Cleveland, Ohio 44114
`General Tel: (216) 586-3939
`Fax: (216) 579-0212
`jvbiernacki@jonesday.com
`Attorneys for Jazz Pharmaceuticals, Inc
`
`
`
`